Parabilis Medicines Files IPO After $2.3B Regeneron Peptide Alliance

Parabilis Medicines, a Cambridge, Massachusetts-based developer of stabilized helical peptides, has filed to go public on the Nasdaq — just days after announcing a strategic research collaboration with Regeneron Pharmaceuticals that could generate up to $2.3 billion in milestone payments. The dual milestone signals growing investor and pharma appetite for peptide-based therapeutics that can reach targets conventional small-molecule drugs cannot.

The company filed its S-1 prospectus on May 20 to list under the ticker PBLS, according to Renaissance Capital, with a placeholder value of $100 million that analysts expect will exceed that figure. Regeneron has also pledged to buy $75 million of Parabilis stock in a concurrent private placement tied to the offering.

What Parabilis’s Helicon platform does

Founded in 2015 as FogPharma and rebranded in 2024, Parabilis has spent a decade engineering what it calls the Helicon platform — stabilized alpha-helical peptides designed to penetrate cell membranes and engage intracellular protein targets, including the flat, featureless surfaces historically considered “undruggable” by both small molecules and biologics.

Unlike conventional peptides — such as BPC-157, TB-500, or the GLP-1 analogues now dominating the compounding market — Parabilis’s Helicons are modified to resist enzymatic degradation while retaining the ability to cross cell membranes. The company is developing them both as stand-alone therapies and as Antibody-Helicon Conjugates (AHCs), a format that marries an antibody’s targeting precision with a peptide payload’s broad intracellular reach.

The Regeneron deal

Under the collaboration announced May 19, Regeneron will contribute its antibody engineering capabilities while Parabilis contributes its Helicon platform. Together they will pursue five therapeutic targets across undisclosed disease areas. Regeneron paid $50 million upfront and committed up to $2.3 billion in development, regulatory, and commercial milestones.

The AHC format is a conceptual evolution of antibody-drug conjugates (ADCs), which have proven effective in oncology but are limited to cytotoxic payloads that kill cells. Parabilis’s Helicon payloads modulate specific intracellular protein function rather than triggering cell death — a distinction that could open doors in therapeutic areas where ADCs have struggled.

Clinical progress

Parabilis’s lead candidate, zolucatetide (formerly FOG-001), is a beta-catenin inhibitor targeting cancers driven by the Wnt signaling pathway — one of the most notoriously difficult targets in oncology. In a Phase 1/2 trial, the drug achieved a 74% objective response rate across several tumor types as a monotherapy. A Phase 3 program in desmoid tumors is expected to begin in the first half of 2027, with additional Phase 1/2 studies in familial adenomatous polyposis and hepatocellular carcinoma already underway.

Before the approval of SpringWorks Therapeutics’ Ogsiveo (nirogacestat) in 2023, there were no FDA-approved therapies specifically for desmoid tumors. Zolucatetide’s intracellular mechanism — blocking beta-catenin-driven transcription — is fundamentally different from the gamma-secretase inhibition of Ogsiveo.

A banner year for peptide biotech

Parabilis’s IPO filing follows a $305 million private financing round closed in January 2026 — itself one of the largest biotech private raises of the year. The company is led by Mathai Mammen, former global head of R&D at Johnson & Johnson.

The Parabilis story is part of a broader trend that PeptidesBeat has tracked throughout May: peptide therapeutics are moving beyond compounding pharmacy grey markets and into mainstream pharmaceutical R&D. The Vector Sciences-MPP manufacturing deal reported yesterday and the AI-designed peptide research covered this month all point to the same inflection point — industrial-scale peptide science is attracting serious capital from both Wall Street and Big Pharma.

If Parabilis prices its IPO successfully, it will be one of the few pure-play peptide platform companies to go public in 2026, offering investors direct exposure to stabilized peptide technology rather than the GLP-1 sales stories that have dominated biotech headlines for the past two years.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.